Personalized medicine in major depressive disorder - Opportunities and pitfalls

Metabolism: Clinical and Experimental

Volumn 62, Issue SUPPL.1, 2013, Pages

  Miller, Diane B ^a   O'Callaghan, James P ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Biomarkers; Genetics; Genome; Metabolism

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FIBROBLAST GROWTH FACTOR; SEROTONIN UPTAKE INHIBITOR; VASCULOTROPIN;

ARTICLE; CLINICAL DECISION MAKING; DOCTOR PATIENT RELATION; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; ENDOPHENOTYPE; GENERAL PRACTITIONER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; GENOTYPE; HUMAN; MAJOR DEPRESSION; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SUICIDE;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NERVE GROWTH FACTORS; NEUROTRANSMITTER AGENTS; PHARMACOGENETICS; PRIMARY HEALTH CARE; QUESTIONNAIRES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84870572475     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.08.021     Document Type: Article

References (38)

1. E. Binder, and F. Holsboer Pharmacogenomics and antidepressant drugs Ann Med 38 2006 82 94
2. A. Halaris A primary care focus on the diagnosis and treatment of major depressive disorder in adults J Psychiatr Pract 17 2011 340 350
3. J.W. Jefferson Clinical and pharmacologic perspectives on the treatment of major depressive disorder CNS Spectr 16 2011 [Sept 11 e-pub ahead of print]
4. B.N. Gaynes, and A.J. Rush Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis Ann Fam Med 5 2007 126 134
5. G.M. Goodwin Major depression is sometimes described as the common cold of psychiatry J Psychopharmacol 22 7 Suppl 2008 3.6
6. A.J. Rush, and H.C. Kraemer Report by the ACNP Task Force on response and remission in major depressive disorder Neuropsychopharmacol 31 2006 1841 1853
7. A.F. Leuchter, and I.A. Cook Biomarkers to predict antidepressant response Curr Psychiatry Rep 12 2010 553 562
8. L. Bartova, and A. Berger Is there personalized medicine for mood disorders? Eur Arch Psychiatry Clin Neurosci 260 Suppl 2 2010 S121 S126
9. American Psychiatric Association Diagnostic and statistical manual of mental disorders, 4th ed, text revision 2000 American Psychiatric Association Washington, DC
10. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder 3rd ed 2010 American Psychiatric Publishing Arlington, VA 17 18 http://www.psychiatryonline.com/pracGuide/ PracticePDFs/PG-Depression3rdEd.pdf
11. H.D. Schmidt, and R.C. Shelton Functional biomarkers of depression: diagnosis, treatment, and pathophysiology Neuropsychopharmacol 36 2011 2375 2394
12. Natnl Institute for Clinical Excellence (NICE) Depression: the treatment and management of depression in adults http://www.nice.org.uk/nicemedia/pdf/ CG90NICEguideline.pdf:2011.
13. A. Tyle, and R. Jones Managing depression in primary care BMJ 330 2005 800 801
14. T.A. Furukawa Assessment of mood guides for clinicians J Psychosom Res 68 2010 581 589
15. M.H. Trivedi Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission J Clin Psychiatry 70 Suppl 8 2009 26 31
16. M.H. Trivedi, and A.J. Rush The inventory of depressive symptomatology, clinican rating (IDS-C and self-report (IDS-SR, and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation Psychol Med 34 2004 73 82
17. D.C. Torpey, and D.N. Klein Chronic depression: update on classification and treatment Cur Psychiatry Rep 10 2008 458 464
18. A.Y.C. Kuk, and J. Li Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care J Clin Psychiatry 71 2010 1502 1508
19. G.E. Simon, and R.H. Perlis Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 167 2010 1445 1455
20. J. Li, A.Y.C. Kuk, and A.J. Rush A practical approach to the early identification of antidepressant medication non-responders Psychological Med 2011 [Ahead of Print]
21. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2002 89 95
22. C.L. Raison, and A.H. Miller Is depression an inflammatory disorder? Curr Psychiatry Rep 13 2011 467 475
23. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. 2011;73:114-26.
24. G.I. Papakostas, and R.C. Shelton Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study Mol Psychiatry 2011 on-line advanced publication, 13 December.
25. R. Keers, and K.J. Aitchison Pharmacogenetics of antidepressant response Expert Rev Neurother 11 2011 101 125
26. C. Holden Depression gene. Back to the drawing board for psychiatric genetics. Science 324 2009 1628
27. M. Wankerl, and S. Wust Current developments and controversies: does the serotonin transport gene-linked polymorphic region (5-HTTLPR) modulate the association between stress and depression? Curr Opin Psychiatry 23 2010 582 587
28. A.F. Leuchter, and I.A. Cook A new paradigm for the prediction of antidepressant treatment response Dialogues Clin Neurosci 11 2009 435 446
29. H. Ledford Depression drug disappoints. Nature 479 2011 278
30. R.H. Howland A benefit-risk assessment of agomelatine in the treatment of major depression Drug Saf 34 2011 709 731
31. P. Olgiati, and E. Bajo Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries Prog Neuropsychopharmacol Biol Psychiatry 36 2012 147 154
32. M.V. Relling, and H.J. Guchelaar Pharmacogenetics: call to action Clin Pharmacol Ther 90 2011 507
33. A. Serretti, and P. Ogiati A model to incorporate genetic testing (5HTTLPR) in pharmacological treatment of MDD World J Biol Psychiatry 12 2011 501 515
34. J. Kirchheiner, and A. Seeringer Pharmacogenetics in psychiatry - a useful clinical tool or wishful thinking for the future? Curr. Pharmaceutical Design 16 2010 136 144
35. A. Seeringer, and J. Kirchheiner Pharmacogenetics-guided dose modification of antidepressants Clin Lab Med 28 2008 619 626
36. B. Grant The ghost of personalized medicine The Scientist 2011 06 14
37. G. Laje, and F.J. McMahon Genome-wide association studies of antidepressant outcome: a brief review Prog Neuropsychopharmacol Biol Psychiatry 35 2011 1553 1557
38. D.W. Nebert, and L. Jorge-Nebert Pharmacogenomics and individualized drug therapy:High expectations and disappointing achievements Am J Pharmacogenomics 3 2003 361 370